This episode of Boston Scientific Talks features Boston Scientific's entrance into advanced endoluminal surgery and obesity management, spearheaded by its acquisition of Apollo Endosurgery in November 2022. Chief Medical Officer, Endoscopy Brian Dunkin, MD and SVP and President, Endoscopy Mike Jones explore the strategic value of this acquisition and the integration of Apollo's technology, which is poised to potentially revolutionize endoscopic procedures. The discussion centers on the potential of Apollo's technology in broadening Boston Scientific's endoluminal surgery capabilities. Jones highlights the addition of the Overstitch device, which enhances the company's ability to perform endoscopic suturing and endoluminal sleeve gastroplasty, addressing obesity through minimally invasive means. Additionally, Dr. Dunkin provides a clinical perspective on how these technologies represent a paradigm shift in surgery, moving towards scarless operations. They also explore the role of GLP-1 medications in the medical device market, underlining how pharmaceuticals complement devices in obesity treatment. The episode gives a comprehensive view of Boston Scientific's strategy in integrating Apollo's technology into its portfolio, the challenges of training and adoption, and the optimism for future innovations in minimally invasive procedures. Thank you to Freudenberg Medical for sponsoring this episode. Please visit Freudenberg Medical’s dedicated webpage at https://www.freudenbergmedical.com/en/single-use-scopes/ to learn more about their specific expertise in this area and to access Freudenberg Medical’s trend paper on the topic. Thank you for listening to the Boston Scientific Podcast. Subscribe to this podcast on every major podcast platform, https://linktr.ee/DeviceTalks

In this special episode of AbbottTalks, recorded live from DeviceTalks West in October 2023, we celebrate a pivotal moment in medical innovation: the 20th anniversary of Abbott's MitraClip™, a revolutionary device introduced in 2003. In the episode, the inventor of the MitraClip, Frederick St. Goar, MD, Interventional Cardiologist, El Camino Health, and Abbott's Santosh Prabhu, PhD, Divisional VP, Global Product Development, discuss the journey of the MitraClip, reflecting on its inception, evolution, and lasting impact on cardiac care over the past two decades. Dr. Goar provides insights into the early challenges and motivations behind inventing the MitraClip, emphasizing its role in transforming minimally invasive cardiac procedures. He reflects on the initial concept, design iterations, and clinical experiences with the device. Dr. Prabhu discusses the continuous enhancements made to the MitraClip since its inception, focusing on improved safety, efficacy, and usability. He highlights the MitraClip's role in reducing hospitalizations and improving patient outcomes, as evidenced by the five-year results from the landmark COAPT™ trial. The episode pays tribute to the legacy of the MitraClip, acknowledging its significant contribution to medical technology and patient care and emphasizing the importance of interdisciplinary collaboration and patient-centric approaches in medical innovation. Thank you to Zeus for sponsoring this episode of AbbottTalks. For more information about Zeus go to www.ZeusInc.com. Thanks for listening to this episode of the AbbottTalks podcast. Please subscribe to the DeviceTalks Podcast Network. COAPT Trial Release -https://abbott.mediaroom.com/2023-03-05-Late-Breaking-Data-from-Landmark-COAPT-TM-Trial-Show-Long-Term-Benefits-of-Abbotts-MitraClip-TM-Device MitraClip History - https://www.abbott.com/corpnewsroom/products-and-innovation/the-mitraclip-story.html#:~:text=MitraClip's%20story%20starts%20in%20California,The%20idea%20was%20unheard%20of.

In the latest episode of MedtechWOMEN Talks, Vivian Golfin, MD, Senior Associate at Intuitive Ventures, shares her expertise on the role of venture capitalists in the medical device product development cycle from the perspective of "The Venture Capitalist." In the episode, Dr. Golfin discusses the significance of early engagement with venture capital firms for startups and how Intuitive Ventures acts as a strategic partner rather than just a financier. She emphasizes the detailed due diligence process, focusing on understanding the risks and potential of medical device startups. Key topics include the importance of milestones like first-in-human trials, early pilot results, and the necessity of feedback in the development process. Dr. Golfin also addresses the evolving role of AI and ML in medical devices and the importance of data diversity. Her insights highlight the need for proactive communication, networking, and leveraging AI for health equity. Thank you to our sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical for providing vital support. https://aptyx.com/ https://catalyzehealthcare.com/ https://confluentmedical.com/ https://www.cretex.com/ Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for supporting MedtechWOMEN Talks!

In the first episode of 2024, co-hosts Tom Salemi and Chris Newmarker bring Jonathan Norris, managing director of HSBC Innovation Banking, into the booth to review the medtech portion of the HSBC Venture Healthcare Report. Last year wasn’t medtech’s strongest, but Jon Norris gives entrepreneurs actionable advice and reason for hope. You can find the entire report on the Linked. Check the feed of Norris and Salemi for a link to the report. Or go here https://www.linkedin.com/feed/update/urn:li:activity:7148682579204800512/ Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network to receive future episodes of our many great shows.

In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses. In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating business segments, building corporate infrastructure, and establishing a dedicated leadership team for the new entity - a major initiative involving over 500 people and a dedicated separation management office. Lastly, Ellingson discusses what's next in Zimmer Biomet's growth strategy, citing a balance between internal innovation and M&A and noting that the company plans to launch over 40 new products in the next 36 months, focusing on markets with at least 4% growth. Thank you to our season one sponsors, AcuityMD and Millstone Medical for supporting this podcast. To learn more about our episode sponsor, AcuityMD, please visit http://acuitymd.com. Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. WATCH and LISTEN below, thank you for supporting Ortho Innovation Talks!

In our final DeviceTalks Weekly of the year, the news team assembles to highlight MassDevice’s Top Medtech Trends of 2023. Let us know if you think we missed something, but we think we recorded all the hits. Thank you for being part of DeviceTalks! We look forward to sharing YOUR stories in 2024. Happy New Year and Go Medtech! Thank you for listening to the DeviceTalks Weekly Podcast. Please subscribe to the DeviceTalks Podcast Network.

This episode of DeviceTalks AI explores the potential for data-driven innovation in healthcare, through conversations with leaders at Microsoft and 1910 Genetics. In the first segment, Elena Bonfiglioli, Global Business Leader for Healthcare, Pharma and Life Sciences at Microsoft, discusses the significance of computation, an essential element of AI investments, in enhancing R&D productivity in healthcare. She emphasizes the need for new approaches to drug development, including shorter clinical trial timelines and the shift toward more efficient R&D. Bonfiglioli also highlights the importance of multimodal data in research and development. In addition, speaks to the integral role of computational methods in drug development, emphasizing how they augment our disease understanding and clinical trial design. In the second segment, Jen Nwankwo, PhD, Founder & CEO of 1910 Genetics - a Y Combinator and Sam Altman-backed startup, shares the innovation strategies around drug discovery. She details their problem-first approach, leading to an integrated, modality-agnostic drug discovery tech stack. Dr. Nwankwo highlights the use of Azure Quantum Elements in accelerating molecular simulations, positioning 1910 Genetics uniquely in designing both small and large molecules. Their global approach to accessible drug discovery through strategic partnerships is emphasized. Join us for the next episode of DeviceTalks AI, featuring an exclusive interview with Ben Newton, Chief Digital Officer and GM of Oncology at GE Healthcare. Thank you to our contributors, some of whom include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support. Tune in and subscribe to DeviceTalks AI on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. WATCH, LISTEN, and READ. Thank you for supporting DeviceTalks AI! Read Now: www.drugdiscoverytrends.com/microsoft-1910-genetics-data-hidden-gems

In this episode, we’ll talk with Medtech Industry Veteran Bill Hunter about the state of Medtech. The CEO of Canary Medical, a leader in medical device sensor technology and data collection, draws lessons from his long career in the industry, sharing his victories and a moment he had previously considered a defeat. Be sure to follow Bill Hunter on LinkedIn. Then, CEO Blake Richards introduces us to Elucid, which developed a software as a service company that can help physicians to better determine the severity of vascular disease. How did Elucid raise over $100 million and venture capital, and what new policies will bolster its bottom line. Thanks for listening to the DeviceTalks Weekly Podcast. Please subscribe to the DeviceTalks Podcast Network.

In the second episode of MedtechWOMEN Talks, our guest Kathryn Rieger, PhD, Sr. Director, Human Factors & User Research at Intuitive, shares her insights on the medical device product development cycle from the perspective of "The Engineer." Drawing from her unique background in military tech and auto tech and her extensive experience in medtech, Dr. Rieger shares insights into how engineers influence the essential stages of the medical device product development cycle. In the episode, Dr. Rieger emphasizes the rigorous nature of verification and validation processes in medtech, underlining the importance of document control and thorough testing to ensure device safety and functionality. She also highlights the role of clinical studies in pre-market validation, underlining the significance of balancing safety considerations with regulatory compliance. Additionally, Dr. Rieger discusses the growing role of AI and machine learning in optimizing development processes while prioritizing user needs and safety. TL;DR - Key takeaways: 1. Integrating user experience and safety is crucial in medical device development. 2. A multidisciplinary approach to medtech product development is key. 3. Effective collaboration and communication are critical to successful product launches. Thank you to our sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical for providing vital support. aptyx.com catalyzehealthcare.com confluentmedical.com cretex.com Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for supporting MedtechWOMEN Talks!

In this episode we’ll talk with Sean Gilligan, chief operating officer at AVS (Amplitude Vascular Systems), about that company’s big play in intravascular lithotripsy, the approached pioneered by vascular leader Shockwave Medical. Gilligan gives some detail on the company’s new approach and shares some insights from his own career as well. We also visit with Steve Levine, Sr. Director, Virtual Human Modeling, and Afrah Shafquat, Senior Data Scientist, both of Dassault Systemes, which sponsored this episode. The pair shared insights on what medical device companies can expect to see from a new set of guidelines being issued for digital simulations in Medtech regarding in silico clinical trials. For more information go to https://www.3ds.com/industries/life-sciences-healthcare/medical-device. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don’t miss an episode.